In market · Revenue
Soil health
An award-winning handheld tool that gives 12+ soil health indicators in minutes in the field, with no sample preparation. Each test is GPS-tagged.
Patented technology · Investor overview
One electronic nose.
Many markets.
ScentsCheck™ reads the volatile organic compounds (VOCs) released by a sample, in minutes. It is already earning revenue in soil health, and the same platform is now moving into AI medical diagnostics, starting with lung cancer and urinary tract infections.
£1.5mRaise now open
RevenueGenerating today in soil health
MinutesFrom sample to AI result
2Medical programmes underway
The platform
A sensor that can be trained to smell almost anything
ScentsCheck™ detects and interprets volatile organic compounds (VOCs) given off by soil, food, animals and people. It combines chemistry, engineering, electronics and AI in a single portable unit that is already manufactured at scale.
Sample releases VOCs
A small sample is placed in the unit, which excites it to release its VOCs.
Sensor reacts
VOCs attach to our proprietary sensor, changing its electrical response.
Digital fingerprint
The response forms a fingerprint specific to that sample.
AI analysis
Machine learning in the cloud interprets the fingerprint.
Results on your phone
Results are delivered straight to a smartphone within minutes.
Minutes, not days
Results on the spot, replacing lab turnaround times of days or weeks.
Many readings, one test
Multiple indicators come from a single sample.
Portable and robust
Built for field conditions, so it works where decisions are made.
Platform markets
Proven in soil. Built for every market where scent carries information.
Each new application is a new model trained on the measurement hardware, not a new product programme. That keeps the cost of entering each market low.
In market · Revenue
Clinical research
Medical diagnostics
A rapid blood test to triage lung nodules after CT, and fast urine screening for suspected UTIs.
See the medical programmes
Opportunity
Animal health
Early, non-invasive signals of disease and welfare issues in livestock.
Opportunity
Food storage
Catching spoilage and rot early to cut waste across the supply chain.
Opportunity
Drinks & manufacturing
Quality control and contamination checks on the production line.
Lung cancer · The problem
Months of uncertainty after a suspicious CT
CT scans often find suspicious lung nodules. Many patients then wait through repeat scans to learn whether those nodules are growing.
False alarms
96.4%
of positive CT screens in the historical NLST trial were false positives.1
Repeat imaging
3 & 12months
The intervals at which selected nodules get repeat CT scans to check for growth.2
Invasive follow-up
Biopsy or surgery
Benign nodules can still lead to invasive diagnostic procedures.
Early diagnosis matters: five-year survival is about 65% at stage I and about 40% at stage II.3
The PES solution
A rapid, low-cost blood test after CT
A new triage step so higher-risk patients are investigated sooner. It is designed to give results in minutes from a prepared serum sample, and to be read alongside CT and clinical risk. The aim is faster decisions with fewer repeat scans and fewer invasive procedures.
CT flags a
lung nodule
lung nodule
PES blood test
+ clinical review
+ clinical review
Higher concernPrompt further investigation
Intermediate concernEarlier repeat CT
Lower concernRoutine surveillance
First patient results
An early clinical signal to build on
A leading German lung cancer clinic · 34 patient serum samples (11 cancer, 23 non-cancer)
91%Sensitivity10 of 11 cancer samples
83%Specificity19 of 23 non-cancer samples
Exploratory cross-validation. The cancer samples were stage IV adenocarcinoma. The next steps are independent and early-stage validation.
Urinary tract infections
Quicker answers for suspected UTIs
UTIs account for more than 10 million UK GP consultations each year. Clinicians often start treatment while they wait for a lab result.
The problem
24–72 hours
to get urine culture results back. Treatment decisions often begin before the answer arrives.
The PES solution
Rapid urine screening
A new AI test on the same platform, designed to support decisions at the point of care.
Early academic study
100%
correct identification in an early study using indole-spiked artificial urine.
Next: patient samples and clinical validation
Traction
Clinical, academic and industry engagement
Two medical programmes are under way, alongside commercial sales in agriculture.
Clinical
Reputable German lung cancer clinic
Patient proof of concept completed34 serum samples analysed. Next come early-stage and independent patient cohorts.
Academic
Scottish academic institute
UTI programme and PhD recruitmentEarly laboratory results in artificial urine. PhD student recruitment is under way.
Industry
Global chemical manufacturer
Evaluation discussionsIn talks with both its medical and agricultural teams about potential applications of the platform.
Development plan
A three-year route to market
Year 1 2026–27
Refine the tests and build datasets
- Lung: add early-stage and broader control samples
- UTI: move into patient samples
Year 2 2027–28
Collect clinical trial evidence
- Prospective studies and independent validation for each intended use
- Assess clinical utility
Year 3 2028–29
Submit for regulatory approval
- Complete technical files and quality requirements
- Line up manufacturing and launch partners
The opportunity
Raising £1.5m
We are targeting a high-value strategic exit in the short to medium term. The funds will take our lung cancer and UTI programmes through the next stage of clinical evidence, on a platform that is already commercial.